Krystal Biotech filings document formal disclosures for a commercial-stage biotechnology company developing and commercializing genetic medicines. Recent 8-K reports furnish quarterly and annual financial results, VYJUVEK net product revenue updates, Regulation FD clinical materials, FDA-related program updates, and commercial launch information for VYJUVEK in Japan.
The company's proxy materials disclose board and shareholder-vote matters, executive compensation, equity awards, ownership information, and governance practices. Together, the filings record how Krystal reports operating performance, capital resources, pipeline and regulatory disclosures, and public-company governance for its HSV-1-based gene therapy platform.
On 30 June 2025, Krystal Biotech (KRYS) filed a Form 4 reporting that independent director Julian S. Gangolli received 5,000 stock options with an exercise price of $137.46 and a 10-year term expiring 30 June 2035. The award vests in 12 equal monthly tranches through June 2026, aligning the director’s incentives with shareholder value over the next year. No common shares were bought or sold, and the grant represents potential dilution of well under 0.1 % of outstanding shares, making it immaterial from a capitalization standpoint.
Krystal Biotech, Inc. (KRYS) filed a Form 4 disclosing an equity compensation grant to director Daniel Janney on 30 June 2025.
- Type of security: Non-qualified stock option (right to buy common shares).
- Quantity: 5,000 options.
- Exercise price: $137.46 per share.
- Vesting schedule: Awards vest in equal monthly installments over 12 months beginning on the grant date.
- Expiration: 30 June 2035 (10-year term).
- Post-transaction beneficial ownership: 5,000 derivative securities reported as directly held; no change in non-derivative share ownership was reported.
The filing represents a routine director compensation grant. The size—5,000 options—equates to a low single-digit percentage of average daily trading volume and an immaterial fraction of KRYS’s ~25 million shares outstanding, implying limited dilution or market impact. No open-market purchases or sales were reported.